Autoimmune hemolytic anemia: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(Created page with "In hematology, '''{{PAGENAME}}''' is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red...")
 
imported>Pat Palmer
(adding subpages)
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
In [[hematology]], '''{{PAGENAME}}''' is an "acquired hemolytic anemia due to the presence of [[autoantibody|autoantibodies]] which agglutinate or lyse the patient's own [[red blood cell]]s."<ref>{{MeSH}}</ref>
{{subpages}}
In [[hematology]], '''{{PAGENAME}}''' (AIHA) is an "acquired hemolytic anemia due to the presence of [[autoantibody|autoantibodies]] which agglutinate or lyse the patient's own [[red blood cell]]s."<ref>{{MeSH}}</ref>


==Classification==
==Classification==
Line 12: Line 13:


==Treatment==
==Treatment==
As of 2010, no [[randomized controlled trial]]s were available.<ref name="pmid21778343">{{cite journal| author=Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA| title=Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. | journal=Blood | year= 2011 | volume= 118 | issue= 15 | pages= 4036-40 | pmid=21778343 | doi=10.1182/blood-2011-05-347708 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21778343  }} </ref> Subsequent studies are below.
[[Rituximab]], a [[monoclonal antibody]], was found to be safe by a [[systematic review]] of 21 studies, although only one was a [[randomized controlled trial]]s.<ref name="pmid25497766">{{cite journal| author=Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS et al.| title=Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. | journal=Autoimmun Rev | year= 2014 | volume=  | issue=  | pages=  | pmid=25497766 | doi=10.1016/j.autrev.2014.11.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25497766  }} </ref>


==References==
==References==
<references/>
<references/>

Latest revision as of 11:55, 8 September 2020

This article is a stub and thus not approved.
Main Article
Discussion
Definition [?]
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In hematology, Autoimmune hemolytic anemia (AIHA) is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red blood cells."[1]

Classification

Diagnosis

Treatment

As of 2010, no randomized controlled trials were available.[6] Subsequent studies are below.

Rituximab, a monoclonal antibody, was found to be safe by a systematic review of 21 studies, although only one was a randomized controlled trials.[7]

References